Progression-free survival as a surrogate endpoint of overall survival in patients with metastatic renal cell carcinoma

Cancer

Volumn 120, Issue 1, 2014, Pages 52-60

  Halabi, Susan ^a,b   Rini, Brian ^c   Escudier, Bernard ^d,e   Stadler, Walter M ^f   Small, Eric J ^g  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b DUKE UNIVERSITY   (United States)

^c TAUSSIG CANCER INSTITUTE   (United States)

^d INSTITUT GUSTAVE ROUSSY   (France)

^e CENTRE LÉON BÉRARD   (France)

^f UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

clinical trials; overall survival; progression free survival; renal cancer; surrogate

Indexed keywords

ALPHA INTERFERON; BEVACIZUMAB; PLACEBO;

ADULT; AGED; ARTICLE; BLOOD PRESSURE REGULATION; CANCER GROWTH; CANCER PATIENT; CONTROLLED STUDY; FEMALE; HUMAN; KIDNEY CARCINOMA; KIDNEY FUNCTION; KIDNEY METASTASIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY;

CLINICAL TRIALS; OVERALL SURVIVAL; PROGRESSION-FREE SURVIVAL; RENAL CANCER; SURROGATE;

AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, RENAL CELL; CLINICAL TRIALS, PHASE III AS TOPIC; DISEASE-FREE SURVIVAL; ENDPOINT DETERMINATION; FEMALE; HUMANS; INTERFERON-ALPHA; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM METASTASIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURVIVAL ANALYSIS;

EID: 84890617204     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28221     Document Type: Article

References (23)

1. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007; 356: 115-124. (Pubitemid 46089672)
2. Hudes G, Carducci M, Tomczak P, et al. Global ARCC Trial. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007; 356: 2271-2281. (Pubitemid 46849157)
3. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007; 356: 125-134. (Pubitemid 46089673)
4. Rini BI, Halabi S, Rosenberg JE, et al. Bevacizumab plus interferon alpha compared with interferon alpha monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol. 2008; 26: 5422-5428.
5. Escudier B, Pluzanska A, Korawleski P, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet. 2007; 370: 2103-2111. (Pubitemid 350296300)
6. Rini BI, Halabi S, Rosenberg JE, et al. Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206 J Clin Oncol. 2010; 28: 2137-2143.
7. Escudier B, Bellmunt J, Negrier S, et al. Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J Clin Oncol. 2010; 28: 2144-2150.
8. Halabi S, Vogelzang NJ, Ou SS, Owzar K, Archer L, Small EJ,. Progression-free survival as a predictor of overall survival in men with castrate resistant prostate cancer. J Clin Oncol. 2009; 27: 2766-2771.
9. Johnson KR, Ringland C, Stokes BJ, et al. Response rate or time to progression as predictors of survival in trials of metastatic colorectal cancer or nonsmall-cell lung cancer: a meta-analysis. Lancet Oncol. 2006; 7: 741-746. (Pubitemid 44283658)
10. Buyse M, Burzykowski T, Carroll K, et al. Progression-free survival is a surrogate for survival in advanced colorectal cancer. J Clin Oncol. 2007; 25: 5218-5224. (Pubitemid 350232253)
11. Heng DY, Xie W, Bjarnason GA, et al. Progression-free survival as a predictor of overall survival in metastatic renal cell carcinoma treated with contemporary targeted therapy. Cancer. 2011; 117: 2637-2642.
12. Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J,. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol. 1999; 17: 2530-2540. (Pubitemid 29368255)
13. Kaplan E, Meier P,. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958; 53: 457-481.
14. Cox DR,. Regression models and life-tables. J R Stat Soc B. 1972; 74: 187-220.
15. Owzar K, Sen PK,. Copulas: concepts and novel applications. Metron. 2003; 61: 323-353.
16. Akritas MG, Siebert J,. A test for partial correlation with censored astronomical data. Mon Not R Astron Soc. 1996; 278: 919-924. (Pubitemid 126430294)
17. Ghosh D,. On assessing surrogacy in a single trial setting using a semicompeting risks paradigm. Biometrics. 2009; 65: 521-529.
18. Efron B,. Better bootstrap confidence intervals (with discussion). J Am Stat Assoc. 1987; 82: 171.
19. Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet. 2008; 372: 449-456.
20. Prentice RL,. Surrogate endpoints in clinical trials: definition and operational criteria. Stat Med. 1989; 8: 431-440. (Pubitemid 19105891)
21. Freedman LS, Graubard BI, Schatzkin A, et al. Statistical validation of intermediate endpoints for chronic diseases. Stat Med. 1992; 11: 167-178.
22. Buyse M, Molenberghs G, Burzykowski T, et al. The validation of surrogate endpoints in meta-analyses of randomized experiments. Biostatistics. 2000; 1: 49-67.
23. Buyse M, Molenberghs G,. Criteria for the validation of surrogate endpoints in randomized experiments. Biometrics. 1998; 54: 1014-1029. (Pubitemid 28429294)